GSK is developing a new hepatitis B drug at the CIIE!

Hepatitis B has always been among the top three in the incidence of legal infectious diseases in China, and the situation of hepatitis B prevention and control in China is still severe
.

The World Health Organization (WHO) puts forward the goal of "eliminating viral hepatitis by 2030", and achieving hepatitis B cure has always been the focus of the world's medical and health industry

At the 4th CIIE, the global hepatitis B treatment leader GlaxoSmithKline (GSK) booth comprehensively demonstrated the full-process management solutions from hepatitis B disease prevention to treatment, and contributed to China's realization of "a future without hepatitis B"
.

For the purpose of achieving functional cure, GSK unveils new hepatitis B drug in research

For the purpose of achieving functional cure, GSK unveils new hepatitis B drug in research

From the launch of the first oral antiviral drug in China in 1999, to now it has a leading product portfolio covering antiviral therapy drugs and vaccines.
GSK has been rooted in China for more than 20 years in the field of hepatitis B and antiviral therapy, and has always been committed to providing patients with effective The treatment plan has benefited more than 1 million Chinese hepatitis B patients
.

At this CIIE, the GSK booth displayed all-round hepatitis B innovative products
.

Among them, it is particularly worth mentioning that GSK is developing a new hepatitis B drug GSK836

According to Pauline Ng, director of prescription medicine at GSK China, GSK836 is an antisense oligonucleotide that binds to the mRNA used to express viral antigens (pathogenic proteins) in liver cells infected with HBV, and then the mRNA is degraded by ribonuclease H.
, leading to premature termination of transcription, inhibition of viral protein HBsAg levels in order to achieve the purpose of functional cure hepatitis B
.

Chronic hepatitis B is a progressive serious disease, and the current treatment plan cannot eradicate the virus
.

Oral antiviral drugs are one of the main therapeutic drugs for hepatitis B treatment.

"At present, there are more and more antiviral drugs, what kind of goals can hepatitis B treatment achieve? What can be seen in the guidelines is that the goal at this stage is to achieve a functional cure.
Functional cure is also called clinical cure.
The liver function is gradually normalized, liver biochemical indicators are normal, and liver tissue lesions are improved; hepatitis B virus cannot be detected; two and a half hepatitis B surface antigens are negative
.

However, patients who can achieve functional cure under existing conditions are relatively It is relatively small, and most patients still need long-term oral antiviral therapy

It is understood that in order to help more patients achieve functional cure or clinical cure, many scientists and companies at home and abroad are working hard to develop new drugs
.

There are many drugs under research, including some antisense oligonucleotides, which bind to viral mRNA to prevent the production of viral proteins; siRNAs, which interfere with and destroy viral RNA; and inhibit surface antigen synthesis

The latest research shows that GSK's new drug GSK836 treatment for 4 weeks can significantly reduce the level of hepatitis B surface antigen (HBsAg) and hepatitis B virus DNA load
.

In August this year, the drug was included in the list of breakthrough treatments by the China Center for Drug Evaluation (CDE), which is expected to "functionally cure" chronic hepatitis B, bringing new hope to the majority of chronic hepatitis B patients

Take multiple measures to help China realize "a future without hepatitis B"

Take multiple measures to help China realize "a future without hepatitis B"

In recent years, with the efforts of all parties, China has achieved remarkable results in the prevention and control of hepatitis B.
However, due to the huge base, China is still a major hepatitis B country
.

Data show that there are about 70 million people infected with chronic hepatitis B virus (HBV) in China, of which about 20 million to 30 million are chronic hepatitis B patients

On the whole, the diagnosis rate and treatment rate of hepatitis B in China are still far from the WHO requirements.
The diagnosis rate of chronic hepatitis B in China is only 22% (VS 90%), and the treatment rate is only 17% (VS 80%).
hepatitis B diagnosis and treatment rates there is still much room for improvement
.

From the launch of the first chronic hepatitis B oral antiviral drug in China to the launch of the oral drug "Veride" in 2014, Huang Jingxuan, head of GSK China’s core prescription drug business department, introduced, “GSK is committed to providing the most innovative drugs for Chinese hepatitis B patients to help improve China's hepatitis B prevention and treatment level
.

In order to benefit more patients, we are also actively participating in medical insurance negotiations, so that good drugs can benefit more patients

It is worth noting that in recent years, GSK has actively participated in the grassroots work of hepatitis B prevention and treatment, and is committed to spreading standardized hepatitis B antiviral treatment to deeper, wider, and more needy areas and populations, so as to improve the current status of local hepatitis prevention and treatment
.

Huang Jingxuan said that due to the imbalance of medical resources between regions, the professional capabilities of the grassroots and underdeveloped areas in the west are relatively weak, and the hepatitis B virus carrying rate and the prevalence of viral hepatitis are still high
.
Therefore, GSK not only strives to improve the accessibility of antiviral treatments, but also through funding related foundations, working with all parties to promote doctor education, patient and public education, and contribute to improving the overall level of China's standardized prevention and treatment of hepatitis B, and ultimately help achieve " There is no future for hepatitis B"
.